Exhibit 99.1
| | | | |
| FOR IMMEDIATE RELEASE | | Contact: | | Jim Mackaness |
| | | | Chief Financial Officer |
| | | | 650 940-4700 |
May 14, 2009
Mountain View, California
IRIDEX Reports First Quarter 2009 Financial Results
IRIDEX Corporation (Nasdaq:IRIX) today reported financial results for the first quarter of 2009 ended April 4, 2009.
For the first quarter of 2009 the Company recorded a net profit of $0.2 million or $0.03 per diluted share compared to a net loss of $0.9 million or $0.10 per diluted share in the first quarter of 2008. Revenue for the first quarter of 2009 was $10.7 million, a 6.4% decrease from the $11.5 million reported for the first quarter of 2008.
Ophthalmology revenues were $7.5 million in the first quarter of 2009 consistent with $7.5 million for the comparable period in 2008. Ophthalmology recurring revenues, comprised of consumable products and service were $4.4 million for the first quarter of 2009, up 6.7% from $4.2 million for the first quarter 2008.
Total Aesthetics revenues were $3.2 million in the first quarter of 2009 compared with $3.9 million in the comparable period of 2008, a decrease of 18.9%.
Gross profit for the first quarter of 2009 was $5.0 million, compared with $4.8 million for the first quarter of 2008. Gross margins were 47.0% and 41.9% for the first quarter of 2009 and 2008, respectively, an improvement of 5.1% of revenues. Operating expenses for the first quarter 2009 were $4.7 million compared with $5.5 million for 2008, or 43.6% and 48.3% of revenues, respectively.
“Returning to profitability given the current distressed economic environment represents a major accomplishment for the company,” stated Mr. Theodore A. Boutacoff, President and CEO. “This is the first quarter that we have been profitable on an operating income level since the fourth quarter of 2005. Keys to achieving profitability during the quarter were improvement in our gross margins to 47% of revenues and managing our operating expenses exceptionally well.
“Our profitable performance during the first quarter reflects steady progress towards successfully implementing our strategic objectives,” Mr. Boutacoff continued, “which are: continuing to manage the Company to be cash flow positive while driving profitability; putting the majority of our focus on our Ophthalmology business and looking to invest in growth opportunities for Ophthalmology.
“During the first quarter our financial strength continued to improve with $0.9 million in cash generated from operations which allowed us to increase our cash balance and at the same time start reducing our bank debt; as a result we now have cash in excess of our debt,” continued Mr. Boutacoff. “We believe our strategy of continuing to focus on our Ophthalmology business is bearing fruit. Our Ophthalmology recurring revenues
have grown quarter over comparable quarter even in these tough times. Furthermore, we announced that the first shipment of the IQ 577, our high-power, true yellow (577 nm wavelength) laser system for use by ophthalmologists was shipped in April for commercial sale, and we see the addition of the IQ 577 to our Ophthalmology product line as reinforcement of the IRIDEX brand for high quality technically advanced Ophthalmology products.”
Cash and cash equivalents were $5.7 million as of April 4, 2009, up from $5.3 million in January 3, 2009, while bank debt was $5.5 million as of April 4, 2009, down from $6.0 million as of January 3, 2009.
Conference Call
IRIDEX management will conduct a conference call later today, Thursday, May 14, 2009 at 5:00 p.m. Eastern Time. Interested parties may access the live conference call via telephone by dialing (877) 941-9205 (U.S.) or (480) 629-9041 (International) and quoting Conference ID 4075884, or by visiting the Company’s website atwww.iridex.com. A telephone replay will be available beginning on Thursday, May 14, 2009 through Thursday, May 21, 2009 by dialing (800) 406-7325 (U.S.) or (303) 590-3030 (International) and entering Access Code 4075884. In addition, later today an archived version of the webcast will be available on the Company’s website atwww.iridex.com.
About IRIDEX
IRIDEX Corporation is a leading worldwide provider of therapeutic based laser systems, consumable laser probes and delivery devices used to treat eye diseases in ophthalmology and skin conditions in the aesthetics market. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 100 independent distributors into 107 countries. For further information, visit the Company’s website athttp://www.iridex.com.
Safe Harbor Statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Act of 1934, as amended, relating to the Company’s financial stability, growth strategy and prospects. Please see a detailed description of these and other risks contained in our Annual Report on Form 10-K for the fiscal year ended January 3, 2009 filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and will not be updated.
IRIDEX Corporation
Condensed Consolidated Statements of Operations
(In thousands, except per share data)
(unaudited)
| | | | | | | | |
| | | Three Months Ended | |
| | | April 4,
2009 | | | March 29,
2008 | |
Revenues | | $ | 10,736 | | | $ | 11,474 | |
Cost of revenues | | | 5,688 | | | | 6,669 | |
| | | | | | | | |
Gross profit | | | 5,048 | | | | 4,805 | |
| | | | | | | | |
Operating expenses: | | | | | | | | |
Research and development | | | 841 | | | | 1,025 | |
Sales and marketing | | | 2,351 | | | | 2,613 | |
General and administrative | | | 1,493 | | | | 1,905 | |
| | | | | | | | |
Total operating expenses | | | 4,685 | | | | 5,543 | |
| | | | | | | | |
Income (loss) from operations | | | 363 | | | | (738 | ) |
Interest and other expense, net | | | (139 | ) | | | (154 | ) |
| | | | | | | | |
Income (loss) before income taxes | | | 224 | | | | (892 | ) |
Provision for income taxes | | | — | | | | — | |
| | | | | | | | |
Net income (loss) | | $ | 224 | | | $ | (892 | ) |
| | | | | | | | |
Net income (loss) per share - basic and diluted | | $ | 0.03 | | | $ | (0.10 | ) |
| | | | | | | | |
Shares used in computing net income (loss) per share - basic and diluted | | | 8,825 | | | | 8,824 | |
| | | | | | | | |
IRIDEX Corporation
Condensed Consolidated Balance Sheets
(In thousands)
(Unaudited)
| | | | | | | | |
| | | April 4,
2009 | | | January 3,
2009 | |
| | | (unaudited) | | | | |
| Assets | | | | | | | | |
Current Assets: | | | | | | | | |
Cash and cash equivalents | | $ | 5,662 | | | $ | 5,307 | |
Accounts receivable, net | | | 7,809 | | | | 8,199 | |
Inventories, net | | | 11,164 | | | | 11,644 | |
Prepaids and other current assets | | | 516 | | | | 540 | |
| | | | | | | | |
Total current assets | | | 25,151 | | | | 25,690 | |
Property and equipment, net | | | 710 | | | | 832 | |
Other intangible assets, net | | | 1,394 | | | | 1,474 | |
Other long term assets | | | 310 | | | | 229 | |
| | | | | | | | |
Total assets | | | 27,565 | | | | 28,225 | |
| | | | | | | | |
| Liabilities and Stockholders’ Equity | | | | | | | | |
Current Liabilities: | | | | | | | | |
Accounts payable | | $ | 1,951 | | | $ | 2,415 | |
Bank line of credit | | | 5,477 | | | | 6,000 | |
Accrued compensation | | | 1,823 | | | | 1,729 | |
Accrued expenses | | | 2,151 | | | | 2,249 | |
Accrued warranty | | | 1,294 | | | | 1,345 | |
Deferred revenue | | | 2,733 | | | | 2,741 | |
Bank term loan | | | — | | | | — | |
| | | | | | | | |
Total current liabilities | | | 15,429 | | | | 16,479 | |
| | | | | | | | |
Stockholders’ Equity: | | | | | | | | |
Convertible preferred stock | | | 5 | | | | 5 | |
Common Stock | | | 89 | | | | 89 | |
Additional paid-in capital | | | 39,244 | | | | 39,105 | |
Accumulated other comprehensive loss | | | (165 | ) | | | (192 | ) |
Treasury stock, at cost | | | (430 | ) | | | (430 | ) |
Accumulated deficit | | | (26,607 | ) | | | (26,831 | ) |
| | | | | | | | |
Total stockholders’ equity | | | 12,136 | | | | 11,746 | |
| | | | | | | | |
Total liabilities and stockholders’ equity | | $ | 27,565 | | | $ | 28,225 | |
| | | | | | | | |
